Natalie Staplin

• Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.

  Mafham MM. et al, (2017), Nephrol Dial Transplant

• Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).

  Staplin N. et al, (2016), American Journal of Kidney Diseases, 68, 371 - 380

• The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review.

  Morton RL. et al, (2016), Nephrol Dial Transplant, 31, 46 - 56

• Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.

  Morton RL. et al, (2016), Am J Kidney Dis, 67, 31 - 39

• Dependent censoring in piecewise exponential survival models.

  Staplin ND. et al, (2015), Stat Methods Med Res, 24, 325 - 341

• Use of gel-based separator tubes to stabilise phosphate in mailed blood samples.

  Herrington W. et al, (2015), Clin Chim Acta, 439, 112 - 114

• Evidence for the Prevention and Treatment of Stroke in Dialysis Patients

  Herrington W. et al, (2015), Seminars in Dialysis, 28, 35 - 47

• Is it time to increase access to transplantation for those with diabetic end-stage kidney disease?

  Chadban SJ. and Staplin ND., (2014), Kidney Int, 86, 464 - 466

• Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).

  Haynes R. et al, (2014), Am J Kidney Dis, 64, 40 - 48

• The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.

  Herrington W. et al, (2014), Clin J Am Soc Nephrol, 9, 914 - 919

• Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)

  Staplin ND. et al, Clinical Journal of the American Society of Nephrology

• Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: UK Heart and Renal Protection (UK HARP)-III. Rationale, trial design and baseline data.

  Haynes R. and Judge P., Nephrology, Dialysis and Transplantation

• Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease

  Herrington W. et al, Hypertension

• Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio

  Herrington W. et al, Clinical Journal of the American Society of Nephrology

• Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies

  Staplin ND. et al, BMC Cancer

Recent Publications

• Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.

  Mafham MM. et al, (2017), Nephrol Dial Transplant

• Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).

  Staplin N. et al, (2016), American Journal of Kidney Diseases, 68, 371 - 380

• The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review.

  Morton RL. et al, (2016), Nephrol Dial Transplant, 31, 46 - 56

• Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.

  Morton RL. et al, (2016), Am J Kidney Dis, 67, 31 - 39

• Dependent censoring in piecewise exponential survival models.

  Staplin ND. et al, (2015), Stat Methods Med Res, 24, 325 - 341